Welcome to the UPF Digital Repository

Early hypertransaminasemia after kidney transplantation: significance and evolution according to donor type

Show simple item record

dc.contributor.author Solà Porta, Eulàlia
dc.contributor.author Redondo Pachón, María Dolores
dc.contributor.author Arias Cabrales, Carlos Enrique
dc.contributor.author Navazo, Diego
dc.contributor.author Buxeda, Anna
dc.contributor.author Burballa Tàrrega, Carla, 1988-
dc.contributor.author Crespo Barrio, Marta
dc.contributor.author García-Retortillo, Montserrat
dc.contributor.author Pascual Santos, Julio
dc.contributor.author Pérez-Sáez, María José
dc.date.accessioned 2022-11-15T08:29:37Z
dc.date.available 2022-11-15T08:29:37Z
dc.date.issued 2021
dc.identifier.citation Solà-Porta E, Redondo-Pachón D, Arias-Cabrales C, Navazo D, Buxeda A, Burballa C, et al. Early hypertransaminasemia after kidney transplantation: significance and evolution according to donor type. J Clin Med. 2021 Nov 4; 10(21): 5168. DOI: 10.3390/jcm10215168
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/54850
dc.description.abstract Early hypertransaminasemia after kidney transplantation (KT) is frequent. It has been associated with the crosstalk produced between the liver and the kidney in ischemia-reperfusion situations. However, the influence of the donor type has not been evaluated. We present a retrospective study analyzing the increase in serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) during the first three months post-KT in 151 recipients who received thymoglobulin as induction therapy, either from brain-death donors (DBD, n = 75), controlled circulatory death donors (cDCD, n = 33), or uncontrolled DCD (uDCD, n = 43). Eighty-five KT recipients from DBD who received basiliximab were included as controls. From KT recipients who received thymoglobulin, 33.6/43.4% presented with an increase in AST/ALT at 72 h post-KT, respectively. Regarding donor type, the percentage of recipients who experienced 72 h post-KT hypertransaminasemia was higher in uDCD group (65.1/83.7% vs. 20.3/26% in DBD and 20.7/27.6% in cDCD, p < 0.001). Within the control group, 9.4/12.9% of patients presented with AST/ALT elevation. One month after transplant, AST/ALT values returned to baseline in all groups. The multivariate analysis showed that uDCD recipients had 6- to 12-fold higher risk of developing early post-KT hypertransaminasemia. Early post-KT hypertransaminasemia is a frequent and transient event related to the kidney donor type, being more frequent in uDCD recipients.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright © 2021 by Solà-Porta E, Redondo-Pachón D, Arias-Cabrales C, Navazo D, Buxeda A, Burballa C, et al. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Early hypertransaminasemia after kidney transplantation: significance and evolution according to donor type
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/jcm10215168
dc.subject.keyword Donor after circulatory death
dc.subject.keyword Early
dc.subject.keyword Hypertransaminasemia
dc.subject.keyword Kidney transplantation
dc.subject.keyword Transaminases
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking